MX2021004138A - Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias. - Google Patents

Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.

Info

Publication number
MX2021004138A
MX2021004138A MX2021004138A MX2021004138A MX2021004138A MX 2021004138 A MX2021004138 A MX 2021004138A MX 2021004138 A MX2021004138 A MX 2021004138A MX 2021004138 A MX2021004138 A MX 2021004138A MX 2021004138 A MX2021004138 A MX 2021004138A
Authority
MX
Mexico
Prior art keywords
chemotherapy
vomiting
formulations
formulation
methods
Prior art date
Application number
MX2021004138A
Other languages
English (en)
Spanish (es)
Inventor
Catherine Jacobson
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of MX2021004138A publication Critical patent/MX2021004138A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021004138A 2018-10-10 2019-10-10 Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias. MX2021004138A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743839P 2018-10-10 2018-10-10
PCT/US2019/055662 WO2020077103A1 (en) 2018-10-10 2019-10-10 Methods and formulations for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
MX2021004138A true MX2021004138A (es) 2021-08-05

Family

ID=68345091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004138A MX2021004138A (es) 2018-10-10 2019-10-10 Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.

Country Status (12)

Country Link
US (1) US20200113847A1 (OSRAM)
EP (1) EP3863614A1 (OSRAM)
JP (1) JP2022502471A (OSRAM)
KR (1) KR20210116432A (OSRAM)
AU (1) AU2019357608A1 (OSRAM)
BR (1) BR112021006858A2 (OSRAM)
CA (1) CA3115985A1 (OSRAM)
CL (1) CL2021000882A1 (OSRAM)
CO (1) CO2021005797A2 (OSRAM)
MX (1) MX2021004138A (OSRAM)
PE (1) PE20211198A1 (OSRAM)
WO (1) WO2020077103A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
CN115968278A (zh) * 2020-05-18 2023-04-14 麦氏生物科技有限公司 脂质-聚合物组合物及使用方法
CA3173494A1 (en) * 2020-09-24 2022-03-31 Michael Foster DAVIS Cannabinoid composition comprising at least 50% carrier
JP7752233B2 (ja) * 2022-07-06 2025-10-09 アバンサール センディリアン ベルハッド 親油性化合物の改善された経口バイオアベイラビリティを有する自己乳化薬物送達配合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
US20050191343A1 (en) * 2003-11-26 2005-09-01 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
EP1881757A4 (en) * 2005-05-13 2008-09-10 Unimed Pharmaceuticals Inc DRONABINOL TREATMENT OF CHEMOTHERAPY-INDUCED POSSIBLE INCOMPATIBILITY AND ILLUSTRATION
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20160279073A1 (en) * 2013-10-31 2016-09-29 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
WO2018058235A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
EP3525764A4 (en) * 2016-10-12 2020-05-13 Columbia Care LLC ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHOD FOR USE THEREOF
EP3565539A4 (en) * 2017-01-03 2020-08-12 Receptor Holdings, Inc. MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS
CN110636834A (zh) * 2017-02-15 2019-12-31 分子浸剂有限公司 制剂
US10307392B2 (en) * 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
WO2019100007A1 (en) * 2017-11-17 2019-05-23 Tilray, Inc. Cannabinoid compositions
EP4417252A3 (en) * 2018-02-23 2024-11-06 Yuzu LV LLC Cannabis based therapeutic and method of use
BR112021001406A2 (pt) * 2018-07-31 2021-04-27 AusCann Group Holdings Ltd composições farmacêuticas auto-emulsificantes sólidas

Also Published As

Publication number Publication date
WO2020077103A1 (en) 2020-04-16
CL2021000882A1 (es) 2021-08-27
CA3115985A1 (en) 2020-04-16
BR112021006858A2 (pt) 2021-07-13
EP3863614A1 (en) 2021-08-18
KR20210116432A (ko) 2021-09-27
PE20211198A1 (es) 2021-07-01
CO2021005797A2 (es) 2021-05-20
AU2019357608A1 (en) 2021-05-27
US20200113847A1 (en) 2020-04-16
JP2022502471A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2019003134A (es) Terapia de combinacion.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2022006712A (es) Metodo para el tratamiento de cancer utilizando celula adyuvante artificial (aavc).